NCT06564467

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

A Phase І, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT202 Injection in Chinese Healthy Participants

• Status: Enrolling By Invitation
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	JMT202	subcutaneous injection
DRUG	Placrbo	subcutaneous injection

Timeline

• Start date: 2024-07-23
• Primary completion: 2025-01-10
• Completion: 2025-07-10
• First posted: 2024-08-21
• Last updated: 2024-08-22

Locations

1 site across 1 country: China